Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Next Previous
Drug Profile

Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Alternative Names: FluBlok Quadrivalent; FluBlok-Q; PSC Flu vaccine (4 strains); Quadrivalent recombinant influenza vaccine seasonal – Protein Sciences Corporation; RIV4; Seasonal quadrivalent influenza vaccine – Protein Sciences Corporation; Supemtek (quadrivalent recombinant influenza vaccine)

Latest Information Update: 15 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Laboratorios Liomont; Protein Sciences Corporation; Sanofi
  • Class Influenza virus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 10 Jan 2024 Sanofi Pasteur terminates phase III trial in in Influenza virus infections (In children, Prevention) in Spain (IM) (NCT05513391, EudraCT2022-000576-19)
  • 29 Sep 2022 Phase-III clinical trials in Influenza virus infections (In adults, Prevention) in Singapore (IM) (NCT05479370)
  • 29 Jul 2022 Phase-III clinical trials in Influenza virus infections (In children, Prevention) in Spain (IM) (EudraCT2022-000576-19)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top